Vybion, Inc. Email Format
Biotechnology ResearchCalifornia, United States2-10 Employees
Vybion, Inc. is a biotechnology research company based in Monterey, California. Its lead program targets Huntington's disease and explores intranasal delivery of exosome-loaded constructs for gene therapy. The firm has developed INT41, a vectorized intrabody designed to counter the disease by binding to a toxic degradation fragment that accumulates in the nucleus and alters gene expression, with activity demonstrated in cell-based systems and in animal models. INT41 has Orphan Disease Designation from the FDA, and a pre-IND meeting defined the basic elements of the IND enabling package. The company describes its work as developing intrabodies to block the toxic function of polyglutamine-expanded proteins linked to inherited neurological disorders.